CoChat
Sign Up
Cited by 98Sarcoidosis and Beryllium Toxicity ResearchHistiocytic Disorders and TreatmentsSystemic Sclerosis and Related Diseases

Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients

Jamilloux, Yvan, Cohen-Aubart, Fleur, Chapelon-Abric, Catherine, Maucort-Boulch, Delphine, Marquet, Alicia, Pérard, Laurent, Bouillet, Laurence, Deroux, Alban +17 more·2017·Seminars in Arthritis and Rheumatism
DOI 10.1016/j.semarthrit.2017.03.005
Open this paper in CoChat — free account

Abstract

Introduction The off-label use of TNF antagonists in refractory sarcoidosis is increasingly reported but data on their efficacy and safety are still insufficient.Objective To report on efficacy and safety of TNF antagonists in severe and refractory sarcoidosis.Methods Examination of retrospective demographic, clinical, therapeutic, and adverse event data on 132 sarcoidosis patients (58% women; mean (min-max) age = 45.5 (14-78) years) given TNF antagonists (mainly infliximab, 91%) and investigation of response-linked factors.Results The overall clinical response (complete and partial) rate was 64%. TNF-antagonist efficacy (i.e., significant decrease of the ePOST score) was noted in cases with neurologic, heart, skin, and upper respiratory tract involvements. No significant difference in efficacy was found between anti-TNF used alone and TNF with immunosuppressant. The use of anti-TNF allowed reducing prednisone dosage at end of follow-up (p < 0.001). Adverse events were observed in 52% of the patients; they included infections (36%) and allergic reactions (8%) and required treatment interruption in 31 cases (23%). When TNF antagonists were interrupted, 13 patients experienced relapses within 14 months on average (median follow-up: 20.5 months).Conclusion TNF antagonists were efficacious in about two-thirds of patients with severe/refractory sarcoidosis but their use led to a high rate of adverse events.

Integrity signals

Registry

Crossref · 10.1016/j.semarthrit.2017.03.005

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Jamilloux, Y., Cohen-Aubart, F., Chapelon-Abric, C., Maucort-Boulch, D., Marquet, A., Pérard, L., Bouillet, L., Deroux, A., Abad, S., Bielefeld, P., Bouvry, D., André, M., Noel, N., Bienvenu, B., Proux, A., Vukusic, S., Bodaghi, B., Sarrot-Reynauld, F., Iwaz, J., Amoura, Z., Broussolle, C., Cacoub, P., Saadoun, D., Valeyre, D., & Sève, P.
Affiliations
  • Lyon 1 Université (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Centre Hospitalier Universitaire de Grenoble (FR)
  • CHU Dijon Bourgogne (FR)
  • Université Sorbonne Paris Nord (FR)
  • Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
  • Centre Hospitalier Universitaire de Caen Normandie (FR)
  • Centre Hospitalier Universitaire de Rouen (FR)
  • Hospices Civils de Lyon (FR)
  • Centre National de la Recherche Scientifique (FR)
Corresponding author
Sève, Pascal
ORCID
Venue
Seminars in Arthritis and Rheumatism
Publisher
Elsevier BV
Published
2017-10
Volume
47
Issue
2
Pages
288-294
ISSN
0049-0172 (ISSN-L)
DOI
10.1016/j.semarthrit.2017.03.005
OpenAlex
W2594015687
Cited by
98
References
33
Citations by year
2026: 3 · 2025: 8 · 2024: 8 · 2023: 13 · 2022: 10 · 2021: 10 · 2020: 17 · 2019: 14 · 2018: 12 · 2017: 2
FWCI
9.10
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Seminars in Arthritis and Rheumatism (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Sarcoidosis and Beryllium Toxicity Research
  • Health Sciences › Medicine › Physiology › Histiocytic Disorders and Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
Keywords
sarcoidosis, refractory sarcoidosis, tumor necrosis factor inhibitors, infliximab, off-label drug use, treatment efficacy, adverse events, infection, immunosuppressants, prednisone dose reduction, relapse
MeSH terms
Infliximab, Adolescent, Adult, Aged, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Retrospective Studies, Sarcoidosis, Tumor Necrosis Factor-alpha, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review